The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead investigator anticipates good news for previous non-responders.
Continue reading »The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B.
Continue reading »While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmless with this non-traditional, non-invasive procedure.
Continue reading »Given to those already infected with Hepatitis C, ChronVac-C® is designed to boost the immune response against the virus. Preliminary trial results report a decrease in viral load of over 95 percent in the first patient to complete ChronVac-C® therapy.
Continue reading »Several researchers at the May 2008 Digestive Disease Week in San Diego reported encouraging progress in their mission to extinguish liver disease. One of the advancements announced includes monitoring dendritic cells to determine which Hepatitis C patients will fare well during treatment.
Continue reading »When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal side effects.
Continue reading »A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C contender, the following six months will determine if its ability to clear the virus lasts.
Continue reading »Currently approved for treating contagious diarrhea in children, nitazoxanide has been found to make pegylated interferon-based treatment for Hepatitis C genotype 4 more effective. Prompting new trials in the U.S. and Europe, this drug is now being evaluated for Hepatitis C genotype 1.
Continue reading »Researchers from Oklahoma have revealed that a drug commonly prescribed for high cholesterol also lowers Hepatitis C viral load. Although not capable of clearing Hepatitis C on its own, a Phase II trial will reveal its effectiveness in combination with interferon and ribavirin.
Continue reading »In addition to demonstrating a Hepatitis C anti-viral effect, an early trial investigating ITMN-191 met safety goals. With this good news, a Phase II study will evaluate this drug in combination with pegylated interferon and ribavirin.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
